drug
Trisenox
Marketedupdated 3mo agoby Teva Pharmaceuticals USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for acute promyelocytic leukemia and neoplasm and 33 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying Trisenox
- phase3Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- phase1ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
- phase3A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)
- phase1Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
- phase3Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- phase1A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that